Generex Biotechnology granted new U.S. drug delivery patent
Patent covers broad claims for the delivery of macromolecules via the buccal cavity of the mouth
The patent relates to the Company's proprietary methodologies for the production of safe and effective oral formulations for the delivery of macromolecular pharmaceutical agents into the human body via the buccal region of the mouth. The process involves the creation of a stable mixed micellar solution containing the pharmaceutical agent, absorption enhancers, and other excipients. When the solution is introduced to the buccal mucosa, the result is increased bioavailability of the active drug and more rapid onset of action.
Most read news
Organizations
Other news from the department research and development
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.